An Oklahoma judge’s ruling that Johnson & Johnson was responsible for helping to fuel the state’s opioid crisis could provide the framework for pending litigation against pharmaceutical companies in other states.
Clinicians and program directors should follow the lead of researchers and measure clinical progress to augment clinical judgment about how treatment is proceeding. But the question quickly becomes: What do we measure?
The National Association for Rural Mental Health's annual conference, held recently in Santa Fe, New Mexico, identified behavioral health challenges in rural areas and offered solutions to address them.
E-cigarettes can be considered “safer” than traditional cigarettes, but a lack of research around their long-term use should prevent them from being considered “safe” in general, CDC Office on Smoking and Health deputy director of research Brian King, PhD, MPH said.
The Substance Abuse and Mental Health Services Administration has proposed a series of revisions to 42 CFR Part 2 regulations to facilitate better care coordination for the treatment of substance use disorders.
It is time to openly discuss the historical failure of a biological model as the primary causation for behavioral health disorders, and engage in a robust evaluation and debate regarding the clinical efficacy of antidepressants in the treatment of depression.
A lengthy report, produced by a panel that was convened by the National Council’s Medical Director Institute, cautions against linking mass violence with mental illness and provides recommendations for providers and other stakeholders.